Aviptadil (CAS 40077-57-4) is a high-purity, pharmaceutical-grade vasodilator synthesized via advanced solid-phase peptide synthesis, fully complying with USP and EP quality standards. Its molecular structure mimics natural vasoactive intestinal peptide (VIP), enabling it to selectively bind to VIP receptors, relax smooth muscle, and dilate blood vessels—particularly in pulmonary and systemic vascular beds. Produced with strict control over peptide purity (≥99%) and biological activity, each batch undergoes rigorous in vitro and in vivo validation, making it a reliable raw material for cardiovascular and respiratory drug formulation.
This potent peptide vasodilator stands out for its targeted action and multifunctional benefits: it effectively reduces pulmonary arterial pressure in patients with pulmonary hypertension, improves blood flow, and supports oxygenation. Unlike non-specific vasodilators, it minimizes systemic hypotension risks with high tissue selectivity, and it also exhibits cytoprotective effects on epithelial cells, making it valuable for respiratory distress-related applications. Its stable chemical structure allows formulation into injectable solutions and aerosols, catering to diverse clinical treatment needs.
Aviptadil (CAS 40077-57-4) caters to professional users: pharmaceutical manufacturers developing cardiovascular/respiratory medications, biotech firms advancing peptide therapies, and research institutions studying vascular biology. Its proven clinical potential, pharmaceutical-grade purity, and targeted mechanism make it a top choice for buyers prioritizing reliability and therapeutic value. Whether for large-scale commercial production or preclinical research, this vasodilator meets the stringent demands of the global pharmaceutical industry.
